Akebia Therapeutics
AKBA
86 hedge funds and large institutions have $176M invested in Akebia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 15 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
20% more capital invested
Capital invested by funds: $147M → $176M (+$29.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 93 → 86 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
49% less call options, than puts
Call options by funds: $1.47M | Put options by funds: $2.86M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.74M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.55M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.99M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.36M |
| 5 |
Renaissance Technologies
New York
|
+$1.08M |
Top Sellers
AKBA Hedge Fund Activity: Q3 2016 in Review
86 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2016, worth a combined $176M — up 20% from $147M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AKBA and 8 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 33 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.74M. The largest seller was Fidelity Investments, cutting an estimated $6.43M.
- 86 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2016, down from 93 in Q2 2016.
- Funds reported $176M of Akebia Therapeutics stock for Q3 2016, up 20% quarter-over-quarter.
- 8 funds opened new Akebia Therapeutics positions in Q3 2016 and 15 closed out, a net change of -7 holders.
- The largest Akebia Therapeutics buyer in Q3 2016 was Avoro Capital Advisors, an estimated $2.74M added.
- The largest Akebia Therapeutics seller in Q3 2016 was Fidelity Investments, an estimated $6.43M sold.
Based on aggregated 13F filings for Q3 2016.